A joint statement was released on 23 May 2021, by the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca. The statement details the risk of TTS is not likely to be increased in people with certain conditions.
The list of conditions for which Comirnaty (Pfizer) is the preferred vaccine has been expanded to also include:
- Past history of idiopathic splanchnic (mesenteric, portal, splenic) vein thrombosis
- Antiphospholipid syndrome with thrombosis
For further information, see Joint Statement from ATAGI and THANZ on TTS and the Use of the COVID-19 Vaccine AstraZeneca.
For clinical guidance see, Mid and North Coast COVID-19 Vaccination HealthPathway
- Username: manchealth
- Password: conn3ct3d